Biotherapeutics News and Research

RSS

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

From Avacta Life Sciences Ltd. 8 Sep 2020

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® AAVX Titer Kit for adeno-associated virus (AAV) vector titer determination in AAV vector manufacturing.

From Gyros Protein Technologies AB 3 Sep 2020

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.

From Avacta Life Sciences Ltd. 3 Sep 2020

New diagnostic tool can predict cancer patients' response to immunotherapy

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.

27 Aug 2020

Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programs incorporating Avacta’s Affimer XT serum half-life extension system.

From Avacta Life Sciences Ltd. 21 Aug 2020

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISION pro-drugs and Affimer immunotherapies.

From Avacta Life Sciences Ltd. 13 Aug 2020

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta Group plc is pleased to announce that it has appointed BBI Solutions to manufacture the saliva-based rapid SARS-CoV-2 antigen test.

From Avacta Life Sciences Ltd. 6 Aug 2020

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.

29 Jul 2020

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta is pleased to announce that it has begun work with the UK government’s CONDOR program to evaluate and clinically validate the COVID-19 laboratory assay.

22 Jul 2020

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta is pleased to announce that it has begun work with the UK government’s CONDOR program to evaluate and clinically validate the COVID-19 laboratory assay.

22 Jul 2020

Avacta and Integumen team up for detection of novel coronavirus in waste water

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Integumen plc (“Integumen”) to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert system to warn of localized COVID-19 outbreaks.

From Avacta Life Sciences Ltd. 14 Jul 2020

Single dose of flu drug can prevent influenza spread among household contacts

A single dose of the flu drug baloxavir marboxil can reduce the spread of the illness within households, new research concludes.

13 Jul 2020

World's first clinical trial of immune-boosting strategy to protect cancer patients from COVID-19

In the race to find new ways to prevent and treat COVID-19, Canadian researchers have launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations - cancer patients.

8 Jul 2020

Innovative clinical trial platform launched to accelerate testing of COVID-19 drugs

The University of Liverpool, Liverpool School of Tropical Medicine and Southampton Clinical Trials Unit announced this week that they have launched their innovative COVID-19 drug testing platform, AGILE.

8 Jul 2020

Berkeley Lights announces Opto™ antigen-presenting bead kit to accelerate the expansion of antigen-specific T cells used to develop cell-based therapies

Berkeley Lights, Inc. today announced the Opto Antigen-Presenting Bead kit, a new reagent kit that activates and expands antigen-specific T cells in blood.

From Bruker Cellular Analysis 25 Jun 2020

Avacta provides update on COVID-19 rapid antigen test development partnership with Cytiva

Avacta Group plc is pleased to announce that the rapid test strips to detect SARS-COV-2 spike protein have been evaluated by Avacta’s partners at Cytiva.

From Cytiva Life Sciences 24 Jun 2020

Human trials to commence using SARS-CoV-2 antibodies from cow's blood

The coronavirus pandemic has sparked a sense of urgency as it actively spreads across the globe. The number of reported cases has now surpassed 8.46 million people, with a death toll of more than 453,000. Scientists and pharmaceutical companies are racing to develop an effective treatment and vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Jun 2020

Avacta provides update on Affimer therapy for COVID-19 infection

Avacta Group plc, is pleased to announce that collaborative work with the University of Glasgow has shown that Affimer reagents prevent infection.

From Avacta Life Sciences Ltd. 18 Jun 2020

C-Path's Transplant Therapeutics Consortium receives positive FDA response for its Letter of Intent

Critical Path Institute announced today that its Transplant Therapeutics Consortium has received a positive response to its Letter of Intent from the U.S. Food and Drug Administration detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program.

17 Jun 2020

Biotherapeutics News and Research

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

New diagnostic tool can predict cancer patients' response to immunotherapy

Avacta expands multi-target collaboration with LG Chem Life Sciences

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta and Integumen team up for detection of novel coronavirus in waste water

Single dose of flu drug can prevent influenza spread among household contacts

World's first clinical trial of immune-boosting strategy to protect cancer patients from COVID-19

Innovative clinical trial platform launched to accelerate testing of COVID-19 drugs

Berkeley Lights announces Opto™ antigen-presenting bead kit to accelerate the expansion of antigen-specific T cells used to develop cell-based therapies

Avacta provides update on COVID-19 rapid antigen test development partnership with Cytiva

Human trials to commence using SARS-CoV-2 antibodies from cow's blood

Avacta provides update on Affimer therapy for COVID-19 infection

C-Path's Transplant Therapeutics Consortium receives positive FDA response for its Letter of Intent

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News